A Single-Center Experience: Integrated Management in Primary Central Nervous System Lymphoma

Area of Science:

• Neuro-oncology
• Hematology
• Immunology

Background:

• Primary central nervous system lymphoma (PCNSL) is a rare, aggressive brain tumor with a guarded prognosis.
• Standard treatment typically involves high-dose methotrexate (HD-MTX) as part of multimodal therapy.
• Management guidelines for PCNSL in immunocompromised patients, particularly those with AIDS, are not well-defined.

Observation:

• The study details the diagnosis and treatment of two PCNSL cases: one immunocompetent and one immunodeficient (AIDS) patient.
• The immunocompetent patient experienced a more conventional disease course.
• The immunodeficient patient required careful management to balance chemotherapy with opportunistic infection risks and drug interactions.

Findings:

• PCNSL management may necessitate distinct protocols based on a patient's immune status.
• Standard treatment protocols may not be directly applicable to immunocompromised individuals.
• Balancing oncological treatment with managing comorbidities is critical in immunodeficient PCNSL patients.

Implications:

• These cases emphasize the need for individualized therapeutic strategies in PCNSL.
• Further research into specific treatment protocols for immunocompromised PCNSL patients is warranted.
• Optimizing PCNSL treatment requires consideration of the patient's immune competency and potential complications.